Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial

Background Patients with diabetes mellitus (DM) have an elevated risk of late events after percutaneous coronary intervention (PCI). The Second-generation Drug-eluting Stents in Diabetes (SUGAR) trial ( NCT03321032 ) compared amphilimus-eluting stents (AESs) and onyx-zotarolimus-eluting stents (O-ZE...

Descripción completa

Detalles Bibliográficos
Autores: Salinas, Pablo, Romaguera, Rafael, Gómez-Lara, Josep, Brugaletta, Salvatore, Gómez-Menchero, Antonio, Martín, Pedro, Romero, Miguel, García-Blas, Sergio, Jiménez, Marcelo, Jiménez, Victor A, Bordes, Pascual, Bayón, Jeremías, Salvatella, Neus, Alameda, Mar, Hyun-Lee, Dae, Trillo-Nouche, Ramiro, López-Benito, María, Frutos, Araceli, Moreu, José, García del Blanco, Bruno, Mohandes, Mohsen, Bosa Ojeda, Francisco, Hernández Hernández, Felipe, Pinar-Bermúdez, Eduardo, Jiménez-Quevedo, Pilar, Rosselló, Xavier, Pocock, Stuart, Sabaté, Manel, Gómez-Hospital, Joan Antoni, Comin-Colet, Josep, Gonzalo, Nieves, Fernández Ortiz, Antonio
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/26440
Acceso en línea:https://hdl.handle.net/20.500.13003/26440
Access Level:acceso abierto
Palabra clave:Diabetes Mellitus
Percutaneous Coronary Intervention
Treatment Outcome
Coronary Artery Disease
Drug-Eluting Stents
Prosthesis Design
Sirolimus
Time Factors
Intervención Coronaria Percutánea
Resultado del Tratamiento
Enfermedad de la Arteria Coronaria
Stents Liberadores de Fármacos
Diseño de Prótesis
Factores de Tiempo
Descripción
Sumario:Background Patients with diabetes mellitus (DM) have an elevated risk of late events after percutaneous coronary intervention (PCI). The Second-generation Drug-eluting Stents in Diabetes (SUGAR) trial ( NCT03321032 ) compared amphilimus-eluting stents (AESs) and onyx-zotarolimus-eluting stents (O-ZESs) in this population. Objectives To report the co-primary endpoint comparing target lesion failure (TLF) between AES and O-ZES at 2 years and the extended follow-up at 3 years. Methods The SUGAR trial enrolled 1175 patients with DM across 23 centres in a randomised (1:1 AES (Cre8EVO) or O-ZES (Resolute Onyx)) assessor-blinded design. The primary endpoint, assessed with a Cox proportional hazards model, was TLF (a composite of cardiac death, target vessel myocardial infarction or ischaemia-driven target lesion revascularisation). Secondary endpoints included all-cause mortality, stent thrombosis and major adverse cardiac events. Results At 2 years, TLF occurred in 60 (10.4%) patients in the AES group and 71 (12.1%) in the O-ZES group; HR 0.84 (95% CI 0.60 to 1.19), p=0.331. At 3 years, TLF occurred in 66 (11.4%) of the AES group compared with 87 (14.9%) of the O-ZES group (HR 0.77; 95% CI 0.56 to 1.06; p=0.106). Landmark analysis revealed no significant differences in TLF rates between 1 and 3 years (HR 1.07; 95% CI 0.62 to 1.87; p=0.801). Rates of individual components of the primary endpoint were comparable between groups. No significant differences were observed in secondary endpoints. Conclusions The SUGAR trial demonstrates that AES and O-ZES provide comparable long-term efficacy in preventing TLF in patients with DM undergoing PCI. These findings support the use of either stent type and highlight the importance of further long-term studies to optimise outcomes. Trial registration number NCT03321032

Similares en LA Referencia